Psychedelic entrepreneur Christian Angermayer has acquired all of Social Chain AG’s shares of European cannabis company SynBiotic.
Apeiron Investment Group, which is the family office and asset management business of entrepreneur and investor Christian Angermayer, is now the largest shareholder of the first German listed cannabis company to pursue an EU-focused buy-and-build investment approach, SynBiotic, with circa 45 per cent.
Angermayer is founder and chairman of biopharmaceutical company atai Life Sciences which is accelerating the development of mental health treatments that address the unmet needs of patients, including ketamaine, psilocybin, ibogaine, MDMA and Salvinorin A, amongst others.
CEO of SynBiotic SE, Lars Müller, commented: “Nature heals – and we want to use the power of cannabinoids to tackle the most burdensome of today’s common ailments in a natural and healthy way.
“Dr Georg Kofler and Social Chain AG have played a very important role in building our platform, and we thank them from the bottom of our hearts for their commitment and input. Passing the baton to Christian comes at a time when the European cannabis industry is on the verge of explosive growth, and we are very proud to have such an experienced healthcare investor and entrepreneur as Christian as our largest shareholder.”
Angermayer says he is sure that SynBiotic SE and cannabinoids in general have a great future ahead of them.
“Whatever the government looks like after the election, in the interests of consumers, it cannot afford to ignore the scientific facts: alcohol, objectively speaking the most harmful of all drugs, is freely available for sale, and even advertising it is permitted,” commented Angermayer.
“Cannabinoid products, risk-free and at the same time displaying positive effects for the consumer, are prohibited. We must finally adapt our drug policy to the scientific facts. No more alcohol and cigarettes. Instead, healthy CBD for everyone.”
Kofler, who was one of the first investors of today’s SynBiotic, added: “Christian Angermayer has single-handedly managed to destigmatise psychedelic substances such as magic mushrooms with his company atai Life Sciences, giving them once again the scientific and medical attention they deserve.
“I am very pleased that he now wants to address the topic of cannabis with the same intensity, and I will maintain friendly relations with SynBiotic SE and the whole team.”